INTRODUCTION
Safe blood transfusion to the people is essential requirement of health care delivery system which can be done
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1 , Bedi N with HIV seroreactivity as 0.2% in blood donations in NACO supported blood banks. 4 India is considered to have intermediate level of Hepatitis B Virus (HBV) endemicity 7 having 3-4.2% of prevalence with more than 40 million HBV carriers.
8 Hepatitis C Virus (HCV) infection in India has a population prevalence of 1%.
9
With increasing voluntary blood donations, prevention of transmission of infectious disease through blood transfusion is challenge in developing, low resource countries. Supply of risk free blood is a challenge and policies and strategies to reduce the risk of Transfusion Transmitted Infection need to be augmented.
Despite the mandatory screening of blood with newest, very sensitive serological test, considerable risk remains for transfusion transmission of virus due to window period infections, occult infections, viral variants or delayed seroconversion. It is now well established that Nucleic Acid Testing (NAT) reduces the window period of Transfusion Transmitted Infection and helps improve blood safety.
10
NAT is used in conjunction with serological tests. NAT can be done individually or in pools.
The primary objective of this study is to analyze the efficacy of MP-NAT testing as additional donor screening programme, seroprevalence of transfusion transmitted infections (TTI) and its role in improving blood safety in the high prevalence population coming to a tertiary care, super-specialty hospital.
MATERIALS AND METHODS
The study was performed at a tertiary-care, NABH accredited hospital from June 2013 to December 2015. At the time of blood collection, donor samples were collected for all mandatory screening serological tests and MP-NAT Testing. ELISA Tests for HIV, HBsAg and HCV were done on Automated EVOLIS System (Bio-Rad). All negative cases were subjected to MP-NAT in small pools of six on Roche's Cobas Taq 
DISCUSSION
With high prevalence of HIV, HBV and HCV in India, safe blood transfusion is a big challenge for the health care system. Transfusion transmitted infections continue to be the biggest threat to the blood transfusion safety. Despite the advancements made in the serological testing of HBV, HCV and HIV, significant transfusion transmission of virus still remains.
New technology like NAT has improvised the blood safety by detecting the virus in the pre-sero conversion window period and thereby providing the sensitivity that is much higher compared to the newest generation serological tests. Though the NAT technology is widely used in the developed countries but the use is limited to a few centers only in high prevalence low resource countries like India.
Our study has shown predominance of replacement donors (96.2%) similar to other studies 2,11-13 where 98.08%, 82.4%, 94.7% and 99.48%, donors respectively were replacement donors. High number of replacement donors reflects lack of awareness in general population, misconception and fears for blood donations and lack of health education.
2 Family donors are not safe as voluntary donors and voluntary, non-remunerated, repeat blood donors are perceived to be safer than the first time blood donors. 3, 14 In this study, all NAT yield cases were replacement donors. There were no voluntary donors.
The overall seropositivity rate in this study of 31 months was around 2.61% which is slightly higher than our previous study of seven years seroprevalence which was 2.11% before inclusion of NAT technology.
2 This marginal increase in overall seroprevalence could be due to detection of window period infections which were not detectable by routine serological tests. This technology limitation puts transfusion recipients to risk for transmissible diseases. The seroprevalence for HIV, HBV and HCV for this study period was 0.18%, 0.68%, and 0.29% respectively which was lower than the overall prevalence of the same in India i.e. 0.26%, 3-4.2%, and 1% respectively. 6, 8, 9 Screening for HIV, HBV and HCV in India is based mainly on serological testing with few centers introducing NAT testing. Most populations in resource limited countries suffer from high prevalence of transfusion transmitted infections and are expected to have more frequent incident and occult cases. 15 Of the 16551 seronegative donor's samples subjected to NAT testing, there were 17 NAT yields (1 in 974). The NAT yield rate from other blood Centers in India is 1 in 753, 16 1 in 610, 17 1 in 1528, 18 1 in 2622, 19 1 in 2000, 20 and 1 in 2972. 15 The higher NAT yield compared to other studies 15, 18, 19, 20 is probably on account of higher prevalence in the population reaching to this tertiary care hospital.
Amongst these 17 cases of NAT yield (1 in 974), HBV NAT yield was 1 in 1379 donations which was almost similar to the yield shown by other studies i.e. 1 in 1012 17 and 1 in 1221. 16 Our HBV NAT yield was higher than those found by Chigurupati et al (1 in 2000) 20 and Chandrashekhar (1 in 26630) 21 which might be due to higher prevalence of HBV in our population.
HBV NAT yield of 1 in 1379 is much higher than studies done in Europe and USA where reported prevalence is 1:600,000 to 1:350,000. 22 Similarly, higher prevalence of HIV-1 and HCV in India as compared to western Europe and USA (1:300,000 to 1:3,000,000) 22, 23 are leading to increased HCV and HIV-1 yield cases as also seen in this study (1 in 4138 and 1 in 16551 respectively) and by Aggarwal et al (HCV yield-1 in 1997) 17 and Kumar et al ( HCV yield-1 in 2536). 16 The plausible explanation for this variation in the yield rate could be due to high prevalence of HBV and HCV in the population as India is considered to be in the intermediate level of HBV endemicity with over 40 million HBV carriers 8 and lesser number of voluntary donations. This has shown a clear advantage of cost effectiveness of NAT screening in developing over developed countries. Developed countries are spending resources on NAT screening to detect only one window period donation in 300,000 to 3,000,000 donations saving three lives while in developing countries with high NAT yield of 1 in 974 (as in this study), NAT screening is 300 to 3000 times more beneficial as compared to developed countries saving much more lives which, in turn, is more cost effective.
This study has certain limitations as viral load through quantitative polymerase chain reaction (PCR) couldn't be performed. The donors in window period donations could not be followed for seroconversion.
However, NAT test with pooling strategies integrated with antibody testing has revolutionized the blood safety by intercepting potentially infectious pathogens. Since viremia precedes seroconversion by several days to weeks, Nucleic Acid Amplification test (NAT) technologies have the potential to detect viremia earlier than routine screening tests based on seroconversion. In countries with high incidence of infection with significant number of window period donations, NAT can serve as a valuable tool to achieve the goal of zero risk of blood. It should be kept in mind that incremental cost-effectiveness of NAT is marginal as compared to safety benefits along with direct cost of medications, monitoring, medical care of the infected person and financial loss of monthly earning as well as other family members of the affected person.
CONCLUSION
With high prevalence of all TTIs in India, implementation of NAT would save more lives of patients and of window period donors by their counselling, early referral to the physicians for close follow up for seroconversion and treatment; further adding the advantage.
With clearer benefits of NAT outweighing cost in providing medical care to the infected person, it is recommended that NAT should be made mandatory by policymakers as a part of TTI testing along with other serological testing to provide safe blood in high prevalence, resource constrained countries like India and it can be a step towards zero risk of blood.
